In 2020, the FDA approved \documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$pemigatinib^{TM}$$\end{document}pemigatinibTM, which targets the hyperactivity of the oncogenetic fibroblast growth factor receptor 2 (FGFR2)—for unresectable advanced BDC [17]. Here, FGFR2 is linked to collecting duct carcinoma.